AstraZeneca’s new vaccine;  a drug that can prevent Covid from becoming fatal

AstraZeneca’s new vaccine; a drug that can prevent Covid from becoming fatal


On Monday, the UK pharmaceutical company AstraZeneca announced positive results from a third phase study to treat symptoms of COVID-19.

AstraZeneca said the drug, which is a combination of two antibodies, resulted in a statistically significant reduction in severe COVID-19 symptoms or deaths in non-hospitalized patients with mild to moderate symptoms.

Read more on AstraZeneca’s new vaccine; a drug that can prevent Covid from becoming fatal…


On Monday, the UK pharmaceutical company AstraZeneca announced positive results from a third phase study to treat symptoms of COVID-19.

AstraZeneca said the drug, which is a combination of two antibodies, resulted in a statistically significant reduction in severe COVID-19 symptoms or deaths in non-hospitalized patients with mild to moderate symptoms.

Also read | Russia stole blueprint for Oxford Covid vaccine to make Sputnik V: Sources

A total of 903 participants took part in the study, 90 percent of whom were at high risk of developing severe COVID-19.

According to information available on the AstraZeneca website, an analysis of participants treated within five days of symptoms appearing found that “AZD7442 reduced the risk of serious COVID-19 illness or death (for whatever reason) 67% “.

View | The United Nations and the World Health Organization come together for a common goal

The treatment, also known as AZD7442, will go into final clinical trials or phase 3 trials to determine its safety and effectiveness.

“With persistent cases of serious COVID-19 infections around the world, there is a significant need for new therapies such as AZD7442 that can be used to protect vulnerable populations … and also help prevent the progression of a serious disease,” said Hugh Montgomery, the study’s lead investigator.

Also read | Vaccines prevent severe Covid, also from Delta: Study

“These positive results indicate that a convenient intramuscular dose of AZD7442 could play an important role in fighting this devastating pandemic.” he added.

In the UK, AstraZeneca’s separate Covid vaccine, developed in partnership with Oxford University, contributed to the rapid response to the Covid threat.

(With contributions from agencies)

.

COMMENTS